

## RESEARCH

### Kajaria Ceramics | Target: Rs 780 | -2% | REDUCE

Margins surprise positively

### Bajaj Auto | Target: Rs 2,800 | -24% | SELL

Operating performance healthy but unsustainable

### JK Tyre & Industries | Target: Rs 70 | -39% | SELL

Good Q3 but rising RM cost and poor sales mix to hurt margins

## SUMMARY

### Kajaria Ceramics

Kajaria Ceramics (KJC) posted an above-expected Q3FY21 with 13% YoY revenue growth and volumes up 11%. EBITDA margins rose 670bps YoY to 21.7% due to lower fuel, employee and other costs, enabling EBITDA/PBT growth of 63%/89% YoY. Management expects volume growth of 20-25%/15% in FY22/FY23 with margins sustainable at 20%. We raise FY21-FY23 earnings 11-19% and roll over to a new Mar'22 TP of Rs 780 (vs. Rs 585), valuing the stock at a revised 30x P/E (vs. 28x). Retain REDUCE on limited upside.

[Click here for the full report.](#)

### Bajaj Auto

Bajaj Auto's (BJAUT) Q3FY21 revenue was in line with projections. EBITDA margin at 19.4% came in ahead of our estimate due to better operating efficiencies and lower staff expense. EBITDA grew 27% YoY and adj. PAT was up 23% to Rs 15.6bn. We expect operating performance to come under pressure given steep RM cost increases coupled with a likely QoQ drop in volumes. We continue to model for a muted 2% earnings CAGR over FY20-FY23. Our Mar'22 TP stays at Rs 2,800, set at 15x one-year forward EPS. Retain SELL.

[Click here for the full report.](#)

## TOP PICKS

### LARGE-CAP IDEAS

Company	Rating	Target
<a href="#">Cipla</a>	Buy	900
<a href="#">GAIL</a>	Buy	155
<a href="#">Petronet LNG</a>	Buy	330
<a href="#">TCS</a>	Buy	3,710
<a href="#">Tech Mahindra</a>	Buy	1,040

### MID-CAP IDEAS

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	3,600
<a href="#">Greenply Industries</a>	Buy	150
<a href="#">Laurus Labs</a>	Buy	410
<a href="#">Transport Corp</a>	Buy	300
<a href="#">Mahanagar Gas</a>	Sell	750

Source: BOBCAPS Research

## DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.08	(1bps)	13bps	(69bps)
India 10Y yield (%)	5.92	1bps	1bps	(72bps)
USD/INR	73.03	0.2	0.7	(2.6)
Brent Crude (US\$/bbl)	56.08	0.3	7.3	(11.3)
Dow	31,188	0.8	3.3	6.9
Shanghai	3,583	0.5	5.5	17.1
Sensex	49,792	0.8	6.0	21.1
India FII (US\$ mn)	19 Jan	MTD	CYTD	FYTD
FII-D	(25.3)	(685.7)	(685.7)	(4,779.3)
FII-E	115.8	2,562.7	2,678.4	32,654.2

Source: Bank of Baroda Economics Research

## BOBCAPS Research

research@bobcaps.in



## JK Tyre & Industries

JK Tyre (JKI) surprised positively on both revenue and earnings in Q3FY21, led by strong replacement demand as well as above-expected gross margins which could stem from low-cost inventory. Revenue increased 26% YoY and operating margin expanded 700bps YoY to 18.1%. We continue to believe that rising input costs will put significant pressure on gross margins and adversely affect earnings. We retain our TP of Rs 70 based on 7x Mar'23E EPS and maintain SELL.

[Click here](#) for the full report.

**REDUCE**

TP: Rs 780 | ▼ 2%

**KAJARIA CERAMICS**

Construction Materials

21 January 2021

**Margins surprise positively**

**Kajaria Ceramics (KJC) posted an above-expected Q3FY21 with 13% YoY revenue growth and volumes up 11%. EBITDA margins rose 670bps YoY to 21.7% due to lower fuel, employee and other costs, enabling EBITDA/PBT growth of 63%/89% YoY. Management expects volume growth of 20-25%/15% in FY22/FY23 with margins sustainable at 20%. We raise FY21-FY23 earnings 11-19% and roll over to a new Mar'22 TP of Rs 780(vs. Rs 585), valuing the stock at a revised 30x P/E (vs. 28x). Retain REDUCE on limited upside.**

Arun Baid

research@bobcaps.in


**Double-digit tile volume growth:** KJC's Q3 revenue increased 13% YoY with tile volumes rising 10.5% YoY whereas sanitaryware & faucets grew 36%. Growth was driven primarily by tier-2-and-below cities with metros returning to 70-75% of pre-Covid sales in the quarter. Management has guided for volume growth of 20-25% in FY22 (on a low FY21 base) and thereafter 15% for the next few years.

**Operating margins expand:** EBITDA margins swelled 670bps YoY to 21.7% due to higher gross margins (+170bps YoY) and lower employee (-190bps) and other expenses (-315bps). EBITDA/PBT thus grew 63%/89% YoY. Management has guided for sustainable 20% operating margins backed by lower A&P cost and operating leverage benefits. We believe margins face headwinds in the near term due to rising gas prices and normalisation of other expenses such as travelling – these may be partly mitigated by operating leverage as volumes rise.

**Maintain REDUCE:** We raise FY21-FY23 earnings by 11-19% to factor in above-expected volume and margin guidance, while resetting our target P/E to 30x (from 28x) – in line with the 5Y average. Rolling valuations forward, we have a revised Mar'22 TP of Rs 780 (earlier Rs 585). Though we like KJC, current valuations of 30.7x FY23E EPS offer limited upside – maintain REDUCE.

Ticker/Price	KJC IN/Rs 795
Market cap	US\$ 1.7bn
Shares o/s	159mn
3M ADV	US\$ 3.8mn
52wk high/low	Rs 840/Rs 296
Promoter/FPI/DII	48%/24%/29%

Source: NSE

**STOCK PERFORMANCE**

Source: NSE

**KEY FINANCIALS**

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	29,562	28,080	26,594	32,220	37,095
EBITDA (Rs mn)	4,495	4,159	4,766	5,811	6,838
Adj. net profit (Rs mn)	2,314	2,553	2,770	3,470	4,121
Adj. EPS (Rs)	14.6	16.1	17.4	21.8	25.9
Adj. EPS growth (%)	(1.2)	10.3	8.5	25.3	18.8
Adj. ROAE (%)	15.8	15.5	15.9	19.1	21.6
Adj. P/E (x)	54.6	49.5	45.6	36.4	30.7
EV/EBITDA (x)	28.3	30.3	26.2	21.5	18.3

Source: Company, BOBCAPS Research



**SELL**

TP: Rs 2,800 | ▼ 24%

**BAJAJ AUTO**

Automobiles

21 January 2021

## Operating performance healthy but unsustainable

**Bajaj Auto's (BJAUT) Q3FY21 revenue was in line with projections. EBITDA margin at 19.4% came in ahead of our estimate due to better operating efficiencies and lower staff expense. EBITDA grew 27% YoY and adj. PAT was up 23% to Rs 15.6bn. We expect operating performance to come under pressure given steep RM cost increases coupled with a likely QoQ drop in volumes. We continue to model for a muted 2% earnings CAGR over FY20-FY23. Our Mar'22 TP stays at Rs 2,800, set at 15x one-year forward EPS. Retain SELL.**

Mayur Milak | Nishant Chowhan, CFA  
 research@bobcaps.in


**Operating performance ahead of estimates:** At Rs 89.1bn, Q3 revenue grew 17% YoY, in line with our estimate. EBITDA margin at 19.4% was better than our projection of 16.7% led by operating efficiencies and lower staff costs (as a percentage of sales). EBITDA was 15% ahead of our forecast at Rs 17.3bn (+27% YoY) and adj. PAT grew 23% YoY to Rs 15.6bn.

Ticker/Price	BJAUT IN/Rs 3,703
Market cap	US\$ 14.7bn
Shares o/s	289mn
3M ADV	US\$ 37.1mn
52wk high/low	Rs 3,807/Rs 1,789
Promoter/FPI/DII	54%/14%/9%

Source: NSE

**RM costs a concern:** With global markets opening up, BJAUT expects steady momentum in exports going ahead. But the sharp rise in prices of key inputs such as aluminium and steel is likely to weaken gross margins by >300bps in Q4 from Q3 levels of 29.2%. The company took price hikes of ~1% in Q3 followed by a further >1% increase in 2Ws during Jan'21 to mitigate the RM cost but would require further hikes to fully pass on the impact. We believe this pass-through would lag cost pressures, undermining operating performance.

## STOCK PERFORMANCE



Source: NSE

**Maintain SELL:** Assuming a 13% decline in FY21 sales, we project a volume CAGR of 1% for BJAUT over FY20-FY23. Operating margins are likely to come off from current levels given RM cost pressure. We build in a revenue/EBITDA/PAT CAGR of 5%/5%/2% over our forecast period and retain our Mar'22 TP of Rs 2,800, set at an unchanged 15x FY23E EPS.

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	302,500	299,187	276,627	315,247	350,681
EBITDA (Rs mn)	49,820	50,962	47,520	52,215	58,776
Adj. net profit (Rs mn)	46,752	50,999	45,639	49,365	54,366
Adj. EPS (Rs)	152.2	176.2	157.7	170.6	187.9
Adj. EPS growth (%)	14.9	9.1	(10.5)	8.2	10.1
Adj. ROAE (%)	22.9	24.5	21.5	20.7	20.4
Adj. P/E (x)	24.3	21.0	23.5	21.7	19.7
EV/EBITDA (x)	21.4	20.7	22.4	20.1	17.7

Source: Company, BOBCAPS Research



**SELL**

TP: Rs 70 | ▼ 39%

**JK TYRE & INDUSTRIES**

Auto Components

21 January 2021

## Good Q3 but rising RM cost and poor sales mix to hurt margins

**JK Tyre (JKI) surprised positively on both revenue and earnings in Q3FY21, led by strong replacement demand as well as above-expected gross margins which could stem from low-cost inventory. Revenue increased 26% YoY and operating margin expanded 700bps YoY to 18.1%. We continue to believe that rising input costs will put significant pressure on gross margins and adversely affect earnings. We retain our TP of Rs 70 based on 7x Mar'23E EPS and maintain SELL.**

Mayur Milak | Nishant Chowhan, CFA

research@bobcaps.in

**Strong Q3:** At Rs 27.7bn (+26% YoY), consolidated revenue was 15% ahead of our estimate aided by strong traction in the farm and MHCV segments.

EBITDA margin surprised positively at 18.1% (11.5% expected), which we believe was due to a higher MHCV tyre sales and low-cost inventory. Adj. PAT for the quarter came in at Rs 1.9bn.

**Surge in commodity prices and adverse sales mix to erode earnings:** With the >30% spike in both rubber and Brent crude prices from Q2FY21 levels, we anticipate gross margin deterioration for tyre companies. Also, higher MHCV tyre sales to OEMs expected in FY22 will have an adverse impact on blended margins. To mitigate the RM cost impact, players will have to effect price hikes of over 15%, which looks difficult. We factor in ~260bps YoY contraction in JKI's FY22 gross margin, resulting in a decline in operating margin and earnings.

**Maintain SELL:** The company's high leverage will continue to weigh on ROE and ROCE despite strong demand. Management believes rising input costs could pressure margins. We model for EBITDA margin shrinkage to 10.2% by FY23 and project a revenue/EBITDA/adj. PAT CAGR of 15%/3%/26% over FY21-FY23. Our Mar'22 TP remains at Rs 70, set at an unchanged 7x FY23E EPS. SELL.

Ticker/Price	JKI IN/Rs 116
Market cap	US\$ 390.4mn
Shares o/s	246mn
3M ADV	US\$ 5.3mn
52wk high/low	Rs 125/Rs 32
Promoter/FPI/DII	56%/3%/1%

Source: NSE

## STOCK PERFORMANCE



Source: NSE

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	103,699	87,249	87,018	104,012	115,118
EBITDA (Rs mn)	10,251	9,876	11,239	10,408	11,785
Adj. net profit (Rs mn)	1,706	2,472	1,718	1,376	2,367
Adj. EPS (Rs)	6.9	10.0	7.0	5.6	9.6
Adj. EPS growth (%)	137.9	44.9	(30.5)	(19.9)	72.0
Adj. ROAE (%)	7.0	10.2	6.6	5.0	8.1
Adj. P/E (x)	16.7	11.5	16.6	20.7	12.0
EV/EBITDA (x)	8.2	8.6	7.2	7.4	6.4

Source: Company, BOBCAPS Research



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 31 December 2020, out of 88 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 14 have ADD ratings, 6 are rated REDUCE and 25 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.